VCNXVACCINEX, INC.vs its industry peers
A metric-by-metric comparison of VACCINEX, INC. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VCNX본 종목 | $4M#4 | — | 0.5x#2 | 6.1x#3 | 5.4%#5 | 8.0%#4 | -3117.3%#7 | -251.4%#4 | -296.0%#4 | — | -63.3%#5 | — |
| TEVJF | — | — | — | — | 4.3%#6 | 186.0%#1 | 12.5%#1 | 18.2%#1 | 5.8%#1 | 7#1 | — | — |
| TLPPF | — | — | — | — | 55.6%#2 | -121.2%#7 | 3.7%#2 | — | — | — | — | — |
| TLSA | $103M#3 | — | — | — | — | 32.9%#3 | — | — | — | — | -49.8%#4 | — |
| TLX | $4.3B#1 | — | — | 5.4x#2 | 55.6%#2 | -121.2%#7 | 3.7%#2 | — | — | — | 35.6%#3 | — |
| UPC | $2M#5 | — | 0.0x#1 | 0.0x#1 | -22.4%#7 | 57.9%#2 | -16.3%#5 | -6.5%#2 | -4.6%#3 | — | 695.0%#1 | 705.9%#1 |
| URGN | $2.0B#2 | — | — | 18.6x#4 | 21.4%#4 | -21.0%#6 | -113.7%#6 | — | — | 2#2 | 130.9%#2 | — |
| VICP | — | — | — | — | — | -20.0%#5 | — | — | — | — | — | — |
| VREOF | — | — | — | — | 170.4%#1 | -143.2%#9 | -0.4%#4 | -15.4%#3 | -0.3%#2 | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-15.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice